Pierre CUQ

Prof. Pierre CUQ

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 1999 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
AEA Evrard
A Evrard
PCPierre CUQ
Pierre CUQ
Joseph CiccoliniJoseph Ciccolini
Joseph Ciccolini
LVL Vian
L Vian
JCJ-P Cano
J-P Cano
5-Fluorouracil (5-FU) and 5′-deoxy-5-fluorouridine (5′-DFUR), a prodrug of 5-FU, are anticancer agents activated by thymidine phosphorylase (TP). Transfecting the human TP cDNA into cancer cells in order to sensitize them to these pyrimidine antimetabolites may be an important approach in human cancer gene therapy research. In this study, an expression vector containing the human TP cDNA (pcTP5) was transfected into LS174T human colon carcinoma cells. Eight stable transfectants were randomly selected and analysed. The cytotoxic effects of 5-FU and 5′-DFUR were higher in TP-transfected cells as compared to wild-type cells. The maximal decreases in the IC50 were 80-fold for 5-FU and 40-fold for 5′-DFUR. The increase in sensitivity to these pyrimidines of TP-transfected cells significantly correlated with the increase in both TP activity and TP expression. Transfected clone LS174T-c2 but not wild-type cells exhibited formation of [3H]FdUMP from [3H]5-FU. In addition the LS174T-c2 clone enhanced the cytotoxic effect of 5′-DFUR, but also that of 5-FU, towards co-cultured parental cells. For both anti-cancer agents, this bystander effect did not require cell–cell contact. These results show that both 5-FU or 5′-DFUR could be used together with a TP-suicide vector in cancer gene therapy.

5 July 2005 in British Journal of Cancer
Verified
Journal Article
Open access
PDP Depeille
P Depeille
PCPierre CUQ
Pierre CUQ
IPI Passagne
I Passagne
AEA Evrard
A Evrard
LVL Vian
L Vian
Glutathione-S-transferase Pi1 (GSTP1) and multidrug resistance protein 1 (MRP1) are overexpressed in melanoma, a skin cancer notoriously resistant to all current modalities of cancer therapy. To investigate the involvement of these detoxifying enzymes in the drug resistance of melanoma, an inducible (Tet-On system) antisense (AS) RNA strategy was used to specifically inhibit GSTP1 expression in A375 cells, a human melanoma cell line expressing high levels of GSTP1 and MRP1. Stable transfectant clones were established and analysed for GSTP1 inhibition by AS RNA. The clone A375-ASPi1, presenting a specific 40% inhibition of GSTP1 expression in the presence of doxycycline, was selected. Lowering the GSTP1 level significantly increased (about 3.3-fold) the sensitivity of A375-ASPi1 cells to etoposide. Inhibitors of glutathione synthesis (BSO), GSTs (curcumin, ethacrynic acid), and also of MRPs (MK571, sulphinpyrazone) improved the sensitising effect of GSTP1 AS RNA. All these inhibitors had stronger sensitising effects in control cells expressing high GSTP1 level (A375-ASPi1 cells in the absence of doxycycline). In conclusion, GSTP1 can act in a combined fashion with MRP1 to protect melanoma cells from toxic effects of etoposide.

1 April 2004 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
PDPhilippe Depeille
Philippe Depeille
PCPierre CUQ
Pierre CUQ
SMSophie Mary
Sophie Mary
IPIsabelle Passagne
Isabelle Passagne
AEAlexandre Evrard
Alexandre Evrard
LVLaurence Vian
Laurence Vian
Previous studies have shown that glutathione S-transferases (GSTs) can operate in synergy with efflux transporters, multi-drug resistance proteins (MRPs), to confer resistance to several carcinogens, mutagens and anticancer drugs. To address the poorly documented role of the GSTM1 in cancer chemoresistance, we used CAL1 human melanoma cells expressing no endogenous GSTM1 and a high level of MRP1. Cells were transfected with an expression vector containing the GSTM1 cDNA, and different clones were selected expressing different levels of GSTM1 (RT-PCR, Western blot, and enzyme activity). Cells overexpressing GSTM1 displayed a 3- to 4-fold increase in resistance to anticancer drugs vincristine (VCR) and chlorambucil (CHB) in proliferation, cytotoxic, and clonogenic survival assays. Inhibitors of MRP1 (sulfinpyrazone, verapamil) and GST (dicumarol, curcumin) completely reversed the GSTM1-associated resistance to VCR, indicating that a MRP efflux function is necessary to potentiate GSTM1-mediated resistance to VCR. Conversely, MRP1 inhibitors had no effect on the sensitivity to CHB. Using immunofluorescence assay, GSTM1 was also shown to protect microtubule network integrity from VCR-induced inhibition of microtubule polymerization. In conclusion, these results show that GSTM1 alone is involved in melanoma resistance to CHB, whereas it can act in synergy with MRP1 to protect cells from toxic effects of VCR.

1 July 2001 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PSP-E Stoebner
P-E Stoebner
PCP Carayon
P Carayon
PCP Casellas
P Casellas
MPM Portier
M Portier
TLT Lavabre-Bertrand
T Lavabre-Bertrand
LML Meunier
L Meunier

1 June 2016 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
ZZZahraa Zghaib
Zahraa Zghaib
JGJean-francois Guichou
Jean-francois Guichou
JVJohanna Vappiani
Johanna Vappiani
NBnicole bec
nicole bec
KHKamel Hadj-Kaddour
Kamel Hadj-Kaddour
PBPierre-Antoine Bonnet
Pierre-Antoine Bonnet

1 March 2006 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
IPIsabelle Passagne
Isabelle Passagne
AEAlexandre Evrard
Alexandre Evrard
PDPhilippe Depeille
Philippe Depeille
PCPierre CUQ
Pierre CUQ
DCDidier Cupissol
Didier Cupissol
LVLaurence Vian
Laurence Vian